Technical feasibility for the Revive + Adrenaline Auto-injector
Technical feasibility for the Revive + Adrenaline Auto-injector
批准号:
56306
负责人:
金额:
$24.3万
依托单位国家:
英国
项目类别:
Study
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
中文摘要
肾上腺素自动注射器(AAI)是给那些易受严重过敏影响的人开的处方,这些人有过敏反应的风险——这是一种危及生命的过敏反应。尽管医生建议要随身携带注射器,但我们的用户研究表明:1。人们并没有尽可能多地携带它们。没有接受肾上腺素治疗过敏性反应是导致死亡的最常见因素,因为肾上腺素是唯一已知的预防过敏性反应死亡的药物。Revive是一个新的AAI概念,是皇家艺术学院(RCA)的毕业项目。该项目旨在扩展前一阶段的有希望的结果,其中开发了概念验证(PoC)。以病人为中心设计,它的体积小得多,便于携带,它的形状使它适合病人的生活。这些因素前所未有地结合在一起,抵消了已确定的问题,即体积太大,无法实际持续地对生活质量产生不利影响,以及明显的医疗形式和相关的耻辱。Revive通过对如何为AAI设计注射器的全新研究实现了这一目标。该专利针头注射系统概念已获得InnovationRCA的支持,并在英国申请专利。我们开发了一个PoC,在那里我们测试了功能和药物剂量。Revive还简化了使用说明,以提高使用的准确性。与目前市场上的大多数产品不同,Revive包含各种针长。现在,该团队试图通过对该概念的工程审计进行技术可行性研究,以扩大这一成就。
英文摘要
An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show:1. People do not carry them nearly as much as they should2. Not receiving adrenaline for an anaphylactic reaction is the biggest common factor in fatalities as adrenaline is the only drug known to prevent death due to anaphylaxis.Revive is a new AAI concept developed as a graduation project at the Royal College of Art (RCA). This project seeks to extend the promising results of this prior phase wherein a proof of concept(PoC) was developed. Designed with the patient at its centre, it's much smaller size makes it easy to carry and its form makes it discreetly fit within a patient's life. These combine like never before to counteract the identified problems of being too large to practically carry continuously and adverse impacts on quality of life from an obvious medical form and associated stigma. Revive achieves this through a fresh examination of how a syringe should be designed for an AAI. The proprietary needle injection system concept has been awarded InnovationRCA's support and is patent pending in the UK.We have developed a PoC where we tested functionality and medicine dosage. Revive also has simplified instructions designed to improve accurate use. Revive, unlike most current offerings in the market, incorporates a variety of needle lengths.Now, the team seeks to extend this achievement by conducting a technical feasibility study through the engineering audit of the concept.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金